
    
      A Phase 2, dose finding safety study to evaluate an individualized monthly VRS-317 dosing
      regimen in adults with GHD. This is an open-label, international, multicenter study with
      VRS-317 treatment for five months. This treatment period will include monthly dose titrations
      until a subject's mean IGF-I SDS value is within a target range for two consecutive months.
      Subjects will be stratified into three cohorts based on sensitivity to rhGH.
    
  